External beam radiation therapy alone for loco-regional recurrence of non-small-cell lung cancer after complete resection

Clinical Evaluation Stereotactic Radiation Therapy for Recurrent or Second Primary Mediastinal Lymph Node Metastases Originating From Non-Small Cell Lung Cancer

“…After SRT, symptoms improved after a median follow-up of 6 days (range, 3-18) for about half of patients, and there was continued alleviation throughout the follow-up period. Our findings concur with published data where palliative RT may improve pain, cough, hoarse, and dyspnea from recurrent NSCLC [35,[43][44].…”

“…In the 1990s and 2000s, reports suggested that patients in patients who had disease involving the MLNs, the levels of disease are independent predictors of patient outcome; subsequently, clinicians have argued to treat these recurrences aggressively, though treatment approaches have been heterogenous [33][34][35]. This is the first study to evaluate the safety and efficacy of SRT (both SBRT and FSRT) for patients with R/SPMLNMs from NSCLC.…”

Non-small cell lung cancer: radiation therapy for locoregional recurrence after complete resection

“…2-5 For locoregional recurrence, radiation therapy is the treatment of choice, and several reports have shown that 2-and 5-year survival is comparable to those for radiation therapy alone in patients with primary stage III non-small cell lung cancer. [6][7][8] Therefore, we have treated these patients with radical radiation therapy when possible.…”

Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer

“…The administration of modern three-dimensional conformal radiotherapy with a curative dose of 60-66 Gy has been reported to achieve approximately 90% response rate (65% complete response and 24% partial response) for postoperative thoracic lymph node recurrence [37] . As a result, the five-year PFS and OS rates are 22.2% and 36.1%, respectively, Postoperative locoregional recurrence is considered to be pathophysiologically the same as originally nonresectable stage ⅢA and ⅢB diseases, although the MST after treatment of a curative dose of radiation is longer for patients with postoperative locoregional recurrence (ranging from 14 mo to 19 mo [38][39][40] ) than for nonresectable stage ⅢA and ⅢB diseases (ranging from 8.5 to 14.1 mo [41] ). The therapeutic outcomes of the nonresectable stage ⅢA and ⅢB disease have been improved with recent developments in chemoradiotherapy, particularly platinum-based regimens, compared with that achieved with radiation alone [41] .…”